Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 2/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22685142 | 0.96 | PDE10A (0.42) | CYP19A1TBXAS1PDE10ACYP1A2CYP2A6 | |
| SCHEMBL21363719 | 0.85 | CYP2A6 (0.50) | PDE10ACYP1A2CYP2A6 | |
| SCHEMBL21636294 | 0.78 | PDE10A (0.43) | CYP19A1TBXAS1PDE10ACYP1A2MELK | |
| SCHEMBL18772842 | 0.78 | KLKB1 (0.41) | CYP19A1TBXAS1PDE10AMAPTMELK | |
| SCHEMBL761399 | 0.77 | CYP2A6 (0.56) | CYP19A1TBXAS1CYP1A2CYP2A6IMPDH2 | |
| SCHEMBL30824503 | 0.77 | CYP2A6 (0.56) | CYP19A1TBXAS1CYP1A2CYP2A6IMPDH2 | |
| SCHEMBL23396667 | 0.77 | CYP1A2 (0.47) | PDE10ACYP1A2CYP2A6 | |
| SCHEMBL23396668 | 0.76 | PDE10A (0.43) | CYP19A1PDE10AIMPDH2NOTUMAKT1 | |
| SCHEMBL18571835 | 0.75 | PDE10A (0.42) | CYP19A1PDE10AMAPTIMPDH2NOTUM | |
| SCHEMBL28298891 | 0.75 | CYP19A1 (0.48) | CYP19A1TBXAS1PDE10AIMPDH2MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815226-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof | ACCRO BIOSCIENCE INC. (KY) | 2020-10-27 | — | — | US | disclosed |
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-02-13 | — | — | US | disclosed |
| US-10450300-B2 | Wnt signaling pathway inhibitors and therapeutic applications thereof | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20190284180-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450300-B2 | Wnt signaling pathway inhibitors and therapeutic applications thereof | WNT1, WNT3A, CTNNB1 | CYP19A1 1684/4885TBXAS1 1031/4885PDE10A 2312/4885 |
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | WNT1, WNT3A, CTNNB1 | CYP19A1 1684/4885TBXAS1 1031/4885PDE10A 2312/4885 |
| US-10815226-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof | LITAF, BAX, TNF | CYP19A1 1980/4885TBXAS1 1156/4885PDE10A 3389/4885 |
| US-20190284180-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | LITAF, BAX, TNF | CYP19A1 1980/4885TBXAS1 1156/4885PDE10A 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.